NVTA earnings

– Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year –  – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating res

SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

– Reported revenue of $117.4 million, a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% –  – Continued improvement in gross margin and ongoing cash burn trends – – Company reiterates key 2023 financial guidance metrics – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2023. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invit

SAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

– In a transaction led by Deerfield Management, the Company effectively addresses ~96% of its 2024 convertible debt obligations – – Participating holders to exchange 90% of their existing 2024 notes for new notes due in 2028 and equitize 10% of their holdings; Certain investors will also provide an additional $30 million of capital – – The Company will discuss this announcement during its fourth quarter and full year 2022 earnings call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Feb. 28, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has signed exchange and financing agreements with a fund managed by Deerfield Man

SAN FRANCISCO, Feb. 14, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae

— Approximately 12% growth year-over-year in revenues —— Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash —— Cash burn continued its declining trend over the past five quarters —— Presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 9:00 a.m. PST — SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced preliminary unaudited fourth quarter and full-year 2022 revenue, cash burn and commercial metrics. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring

SAN FRANCISCO, Oct. 25, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

— Continued to execute towards operational excellence with portfolio optimization, broad cost controls and cash management — — Recently announced realignment plan is expected to extend the company's cash runway to the end of 2024; Maintain financial guidance — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time — SAN FRANCISCO, Aug. 9, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2022. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring

SAN FRANCISCO, Aug. 2, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

—   Exiting non-core businesses and geographies to prioritize higher-margin business initiatives — —   Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — —   Provides preliminary revenue and gross margin ranges for the second quarter of 2022; amends full-year 2022 financial guidance — — Conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time — SAN FRANCISCO, July 18, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading genetics platform. The plan introduces a significant realignment of the company's operatio

— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than $100 million — — Broad OPEX controls and portfolio optimization to decrease spend, extend runway through 2023— — Company lays out path for continued industry-leading growth while achieving positive operating cash flow by end of 2025 — — Technology Day investor forum to be held week of July 11, roadmap for the creation of a new category in healthcare — — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time — SAN FRANCISCO, May 3, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today anno

SAN FRANCISCO, April 20, 2022 /PRNewswire/ -- Invitae Corporation (NYSE:NVTA), a leading medical genetics company, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporat

SAN FRANCISCO, Feb. 10, 2022 /PRNewswire/ -- Invitae Corporation (NYSE:NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNews

SAN FRANCISCO, Jan. 10, 2022 /PRNewswire/ -- Invitae Corporation (NYSE:NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and commercial metrics reporting approximately 64 percent growth in revenue and 76 percent growth in volume, signaling continued momentum into 2022. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE:NVTA), a leading medical genetics company, today announced that it will report its third quarter 2021 financial results on Monday, November 8, 2021, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corpo

SAN FRANCISCO, Sept. 7, 2021 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making.

SAN FRANCISCO, July 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corpo